216 related articles for article (PubMed ID: 9290780)
1. Dose adjustment and cost of itraconazole prophylaxis in lung transplant recipients receiving cyclosporine and tacrolimus (FK 506).
Kramer MR; Merin G; Rudis E; Bar I; Nesher T; Bublil M; Milgalter E
Transplant Proc; 1997 Sep; 29(6):2657-9. PubMed ID: 9290780
[No Abstract] [Full Text] [Related]
2. Itraconazole prophylaxis in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interaction.
Shitrit D; Ollech JE; Ollech A; Bakal I; Saute M; Sahar G; Kramer MR
J Heart Lung Transplant; 2005 Dec; 24(12):2148-52. PubMed ID: 16364864
[TBL] [Abstract][Full Text] [Related]
3. Fungal infection in heart-lung transplant recipients receiving single-agent prophylaxis with itraconazole.
Hayes D; Ball AM; Mansour HM; Martin CA; Flynn JD
Exp Clin Transplant; 2011 Dec; 9(6):399-404. PubMed ID: 22142048
[TBL] [Abstract][Full Text] [Related]
4. Overview of tacrolimus-based immunosuppression after heart or lung transplantation.
Reichenspurner H
J Heart Lung Transplant; 2005 Feb; 24(2):119-30. PubMed ID: 15701425
[TBL] [Abstract][Full Text] [Related]
5. [Immunosuppression with tacrolimus (FK 506) and cyclosporin A for preventing graft rejection after liver transplantation. Retrospective evaluation of medical costs based on the FG-O157 Study in 224 patients (Germany)].
Bachinger A; Kirchhoff D; Rychlik R
Chirurg; 1998 Sep; 69(9):957-62. PubMed ID: 9816454
[TBL] [Abstract][Full Text] [Related]
6. Voriconazole and itraconazole in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interaction.
Kramer MR; Amital A; Fuks L; Shitrit D
Clin Transplant; 2011; 25(2):E163-7. PubMed ID: 21158923
[TBL] [Abstract][Full Text] [Related]
7. Pharmacoeconomic study of tacrolimus-based versus cyclosporine-based immunosuppressive therapy following liver transplantation.
Rabkin JM; Corless CL; Rosen HR; Olyaei AJ
Transplant Proc; 2001; 33(1-2):1532-4. PubMed ID: 11267411
[No Abstract] [Full Text] [Related]
8. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients.
Shenoy S; Hardinger KL; Crippin J; Korenblat K; Lisker-Melman M; Lowell JA; Chapman W
Liver Transpl; 2008 Feb; 14(2):173-80. PubMed ID: 18236391
[TBL] [Abstract][Full Text] [Related]
9. Long-term comparison of tacrolimus versus cyclosporine in liver transplantation. The US FK Study Group.
Wiesner RH
Transplant Proc; 1998 Jun; 30(4):1399-400. PubMed ID: 9636565
[No Abstract] [Full Text] [Related]
10. Assessment of the frequency and costs of posttransplantation hospitalizations in patients receiving tacrolimus versus cyclosporine.
Neylan JF; Sullivan EM; Steinwald B; Goss TF
Am J Kidney Dis; 1998 Nov; 32(5):770-7. PubMed ID: 9820446
[TBL] [Abstract][Full Text] [Related]
11. Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients.
Penninga L; Penninga EI; Møller CH; Iversen M; Steinbrüchel DA; Gluud C
Cochrane Database Syst Rev; 2013 May; (5):CD008817. PubMed ID: 23728681
[TBL] [Abstract][Full Text] [Related]
12. Tacrolimus in solid organ transplantation: an update.
Shapiro R
Transplant Proc; 1999 Sep; 31(6):2203-5. PubMed ID: 10500545
[No Abstract] [Full Text] [Related]
13. Controversies in heart and lung transplantation immunosuppression: tacrolimus versus cyclosporine.
Kobashigawa JA
Transplant Proc; 1998 Jun; 30(4):1095-7. PubMed ID: 9636445
[No Abstract] [Full Text] [Related]
14. Tacrolimus Versus Cyclosporine as Primary Immunosuppressant After Renal Transplantation: A Meta-Analysis and Economics Evaluation.
Liu JY; You RX; Guo M; Zeng L; Zhou P; Zhu L; Xu G; Li J; Liu D
Am J Ther; 2016; 23(3):e810-24. PubMed ID: 25299636
[TBL] [Abstract][Full Text] [Related]
15. [Cyclosporine versus tacrolimus in kidney transplants in Brazil: a cost comparison].
Guerra Junior AA; Acúrcio Fde A; Andrade EI; Cherchiglia ML; Cesar CC; Queiroz OV; Silva GD
Cad Saude Publica; 2010 Jan; 26(1):163-74. PubMed ID: 20209220
[TBL] [Abstract][Full Text] [Related]
16. Conversion of liver allograft recipients from cyclosporine A to FK 506 immunosuppressive therapy.
Ben-Ari Z; Mor E; Shaharabani E; Bar-Nathan N; Shapira Z; Tur-Kaspa R
Transplant Proc; 2000 Jun; 32(4):709-10. PubMed ID: 10856553
[No Abstract] [Full Text] [Related]
17. Tacrolimus (FK 506) therapy is associated with a significant reduction in immunosuppressive treatment failures following primary liver transplantation.
Bechstein WO; Neuhaus P; McMaster P; Calne R; Pichlmayr R; Otto G; Williams R; Ericzon BG; Bismuth H
Transplant Proc; 1996 Apr; 28(2):1008-10. PubMed ID: 8623211
[No Abstract] [Full Text] [Related]
18. Tacrolimus or cyclosporine for immunosuppression after cardiac transplantation: which treatment reveals more side effects during long-term follow-up?
Groetzner J; Meiser BM; Schirmer J; Koglin J; vScheidt W; Klauss V; Cremer P; Reichenspurner H; Reichart B
Transplant Proc; 2001; 33(1-2):1461-4. PubMed ID: 11267373
[No Abstract] [Full Text] [Related]
19. Advantage--FK 506: reduced chronic rejection for lung transplant recipients.
Bolman RM
Ann Thorac Surg; 1995 Sep; 60(3):495-6. PubMed ID: 7545888
[No Abstract] [Full Text] [Related]
20. [Comparison between tacrolimus (FK 506) and cyclosporin in immunosuppressive therapy after liver transplantation].
Arnold JC; Theilmann L
Z Gastroenterol; 1995 Oct; 33(10):624-5. PubMed ID: 7502559
[No Abstract] [Full Text] [Related]
[Next] [New Search]
